Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

National Institutes of Health (NIH)

Status and phase: Unknown; Phase 1

Conditions: Amphetamine-Related Disorders

Treatments: Drug: Selegiline

Study type: Interventional

Funder types: NIH

Identifiers

NCT00033072

NIDA-CTO-0004-1

Details and patient eligibility

About

The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.

Full description

To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg & 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals
• Be able to verbalize understanding of consent form; provide written informed consent

Exclusion criteria

• Please contact site for more information